arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences, Innovation

FT Pharma AI and Data Summit

Improving analysis and decision-making in R&D and beyond

Boston |
Speakers include:
Sarah Neville

Sarah Neville

Financial Times

Hannah Kuchler

Hannah Kuchler

Financial Times

Overview

Artificial intelligence and data analytics are increasingly valuable tools for pharma companies, enabling them to accelerate clinical trials and unlock the value of products earlier. As data applications become more advanced, the whole healthcare value chain could be affected. New forms of drug discovery will emerge and pharma workforces will need to evolve. At the same time, the collection of real-world evidence using AI platforms will alter the role of patients. 

Join us at the FT Pharma AI and Data Summit in Boston on March 4, 2021, to find out how artificial intelligence and data analytics can be deployed effectively in drug discovery, clinical trials, market access and other areas. Gain valuable insights into the opportunities and risks different stakeholders may face in the age of AI, where everything is defined by data.

fallback
fallback Add to my Calendar 10/01/2020 08:00:0010/01/2020 17:00:00trueFT Pharma AI and Data SummitArtificial intelligence and data analytics are increasingly valuable tools for pharma companies, enabling them to accelerate clinical trials and unlock the value of products earlier. As data applications become more advanced, the whole healthcare value chain could be affected. New forms of drug discovery will emerge and pharma workforces will need to evolve. At the same time, the collection of real-world evidence using AI platforms will alter the role of patients. Join us at the FT Pharma AI and Data Summit in Boston on March 4, 2021, to find out how artificial intelligence and data analytics can be deployed effectively in drug discovery, clinical trials, market access and other areas. Gain valuable insights into the opportunities and risks different stakeholders may face in the age of AI, where everything is defined by data.FT-Pharma-AI-and-Data-Summitc4f211a3871aa3fa8be1fc514ff6cfc9MM/DD/YYYY

Register your interest

Chair and Moderators (2)

Sarah Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville is Global Pharmaceuticals Editor of the Financial Times, a position she has held since 2016. She joined the Financial Times in 2001 and has held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and Public Policy Editor. She began her career on local and regional newspapers, eventually becoming Political Editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. 

Hannah Kuchler

Hannah Kuchler

US Pharma and Biotech Correspondent
Financial Times

Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York.  Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.

KEY QUESTIONS TO BE ADDRESSED

  • How is AI being used as a tool for drug discovery?
  • What is the role of AI in developing vaccines and therapeutics for COVID-19?
  • How are companies using AI to extract value from data to produce real-world evidence?
  • How can pharma company cultures be adapted to the rise of AI
  • How can AI help pharma companies to become more patient-centric?
fallback

HOW THIS EVENT IS DIFFERENT

Events covering AI and data in pharma often take a limited view of their impact across the entire product lifecycle. We will approach the subject with a view to assessing the potential of data applications at every step from laboratory to patient while recognizing the challenge of bridging the gap between innovation and implementation.

fallback

WHO WILL BE THERE?

Wherever you work and whatever you do in healthcare and life sciences, this event will give you fresh perspectives on how to be part of pharma’s data-driven future.

fallback

SPONSORSHIP OPPORTUNITIES

  • Gain access to 200 senior executives and influential stakeholders from across the US;
  • Brand alignment with the FT and its unrivalled credibility;
  • Demonstrate thought-leadership on the latest data applications;
  • Benefit from sustained international visibility through our advertising and marketing campaigns

Joe Hames
Sector Head - Pharma and Healthcare
M: +44 791 329 2038
E: joe.hames@ft.com

fallback

PRESENTED BY (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

Knowledge Partner (1)

McKinsey & Company is a global management consulting firm committed to helping organisations create Change that Matters.

In more than 130 cities and 65 countries, our teams help clients across the private, public and social sectors shape bold strategies and transform the way they work, embed technology where it unlocks value, and build capabilities to sustain the change. Not just any change, but Change that Matters – for their organisations, their people, and in turn society at large.

Associate Sponsor (1)

hub.brussels is the economic development agency of the Brussels-Capital Region (Belgium).

hub.brussels aims to showcase Brussels as the most attractive location for business creation and development in Europe.

hub.brussels fosters health care and life sciences related projects through its dynamic lifetech.brussels cluster

hub.brussels offers customized support, free tools, and recognized expertise to help entrepreneurs boost their autonomy, streamline their decision-making, expand their knowledge, and widen their networks. The agency helps these entrepreneurs excel in gaining client trust and pushes them to grow  in Brussels… and beyond.

hub.brussels is above all the sum product of over 300 dedicated, thorough, and passionate collaborators determined to support, encourage, and propel the most innovative and audacious businesses towards success…

hub.brussels’ North-America offices are located in New York City, San Francisco, Montréal and Vancouver

Media Partner (1)

MassBio® is a not-for-profit organization founded in 1985 that represents and provides services and support for the world’s leading life sciences supercluster.
 
MassBio is committed to advancing Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives.
 
Representing 1,200+ biotechnology companies, academic institutions, disease foundations and other organizations involved in life sciences and healthcare, MassBio leverages its unparalleled network of innovative companies and industry thought leaders to advance policy and promote education, while providing member programs, events, industry information, and services.

CONTACT US

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
FT Live Delegate Services - EMEA
Delegate Booking and Registration Enquiries
Financial Times
Ciaran Larkin
Speaking Opportunities
Financial Times Live
Joe Hames
Sponsorship & Exhibitor Opportunities
Financial Times